Kasabach-Merritt phenomenon in a neonatal kaposiform haemangioendothelioma

Kasabach–Merritt phenomenon and prenatal counseling: a case series

“…There is also no established consensus on exact timing and coordination of delivery. Extreme prematurity (as in case 1) has been described to reduce treatment chances, highly increasing the mortality rate . A better outcome has been described with moderate prematurity .…”

Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach‐Merritt phenomenon

“…1,2 KMP is a rare, life-threatening coagulopathy characterized by rapid lesional growth accompanied by thrombocytopenia, fibrinogen consumption, and elevated D-dimers. 3,4 KMP mainly appears in newborns and infants, with mortality estimated at 10-30%. 5,6 We present two cases of refractory KMP that improved with low-dose of sirolimus.…”

“…TA is typically a solitary lesion, but multiple lesions have been described . KMP is a rare, life‐threatening coagulopathy characterized by rapid lesional growth accompanied by thrombocytopenia, fibrinogen consumption, and elevated D‐dimers . KMP mainly appears in newborns and infants, with mortality estimated at 10‐30% .…”

Case Report: Kaposiform Hemangioendothelioma With Spinal Involvement

“…Epidemiological surveys have shown that the incidence of KHE is approximately 0.71/100,000 in children (1). KHE can be accompanied by a severe complication known as the Kasabach-Merritt phenomenon (KMP), which is characterized by thrombocytopenia, hypofibrinogenemia, and clotting factor consumption (2)(3)(4)(5). According to the morphology and the clinical manifestations, Ji (6) divided KHE into three types, namely, superficial (which is limited to the skin and subcutaneous soft tissue without the invasion of muscles and bones, chest and abdominal cavity), mixed (which involves both the skin and subcutaneous deep muscles, bones and/or joints) and deep (which has no skin manifestations).…”